Skip to main content
Wassim Abida, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

WassimAbidaMD

Oncology New York, NY

Physician

Overview of Dr. Abida

Dr. Wassim Abida is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 8 years. He is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 80 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2009 - 2011
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 2009

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • NY State Medical License
    NY State Medical License 2011 - 2024
  • PA State Medical License
    PA State Medical License 2009 - 2011
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant pro... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Microsatellite instability in prostate cancer and response to immune checkpoint blockade. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer
    Expert Answers to Questions on PARP Inhibitor Combinations in Prostate CancerJune 30th, 2021
  • Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
    Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual MeetingFebruary 11th, 2021
  • Rubraca (Rucaparib) Approved in the U.S. As Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Rubraca (Rucaparib) Approved in the U.S. As Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)August 26th, 2020
  • Join now to see all

Hospital Affiliations